US-based AcelRx Pharmaceuticals has started dosing in the pivotal Phase III trial of ARX-04, a non-invasive, single-use 30mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator (SDA), for the treatment of pain.
Scheduled to be conducted at four sites in the US, the multi-center, double-blind, placebo-controlled SAP301 trial will evaluate the efficacy and safety of ARX-04 vs. placebo to treat moderate-to-severe acute pain following ambulatory abdominal surgery.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A total of 160 adult patients will be included in the trial and they will be randomised 2:1 active to placebo, to be treated for about 48 hours.
During the trial, ARX-04 or placebo will be administered by site staff as requested by the patient, but it will not be more than once per hour.
The trial’s primary endpoint is to show a significant difference in the time-weighted summed pain intensity difference (SPID) of ARX-04 compared to placebo over a 12-hour dosing period (SPID-12).
AcelRx founder and chief medical officer Dr Pamela Palmer said: "We are pleased to have our pivotal ARX-04 Phase III clinical trial underway.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"The ARX-04 product represents a promising new application of our sublingual tablet technology for delivery of sufentanil and has the potential to safely provide non-invasive, fast-acting analgesia for patients in acute pain.
"We anticipate enrollment to take up to nine months. Pending the completion of enrollment in this study, we anticipate top-line results in the fourth quarter of 2015."
ARX-04 includes 30mcg sufentanil sublingual tablet, in a pre-filled SDA and the company’s tablet formulation enables sublingual sufentanil absorption when the drug is placed under the tongue.
As a result, ARX-04 can provide analgesia in a non-invasive method of administration and show a consistent pharmacokinetic profile due to a high percentage of drug being absorbed sublingually instead of through the gastrointestinal tract.
